

TOP PAPERS

Assoc. Prof. Adrian G. Tase

1. Inventia 4 desen nr. 021582/28.06.2017 NaCl, Inventia 3 desen nr. 021346/29.09.2016 vK, Inventia 2 desen nr. grafica fisa medicala, Inventia 1 desen nr. 021197/31.03.2016.
2. A.G. Tase, O. T. Țețiu, G. Săvoiu, G. Stănciulescu, S. Azamfire, L. Vijan, B. Nita, I. Iorga-Simăn. Poster III Nr. 33. Persistent sinus tachycardia in patients with hyperthyroidism could be lasting reduced by ivabradine continuous therapy – a 48 months study. *Romanian Journal of Cardiology CNCSIS B+ EBSCO Indexed Journal, Indexed Journal in the ESC search engine, Supplement on CD, 2016.* www.romanianjournalcardiology.ro
3. A.G. Tase, O. T. Țețiu, A. Tase, G. Săvoiu, M. Mihăilă, I. Iorga-Simăn, M.g. Man. Poster V Nr. 21. New onset left ventricular dysfunction +/- incidental heart failure in Epirubicinum recipients for breast cancer could be improved by trimetazidine. *Romanian Journal of Cardiology CNCSIS B+ EBSCO Indexed Journal, Indexed Journal in the ESC search engine, Supplement on CD, 2016.* www.romanianjournalcardiology.ro
4. A.G. Tase, G. Săvoiu, O. T. Țețiu, A. Tase, M. G. Man, G. Stănciulescu, M. Mihăilă, I. Iorga-Simăn. Uninterrupted ivabradine treatment may provide lasting reduction of persistent sinus tachycardia with preserved airways physiology in lung cancer patients: a 48 months study. Posters, p. 47, Final Programme, EBAC, ESC Congress Barcelona 2017, 26-30 August www.escardio.org/ESC20167, <http://congress365.escardio.org/>

5. A. G. Tase, L. Vijan, G. Chirita, G. Savoiu, O. T. Țețiu, I. Iorga-Siman. Ivabradine continuous therapy may provide lasting reduction of persistent sinus tachycardia in patients with hyperthyroidism – a 48 months retrospective study. *Asian Pacific Congress of Cardiology, Singapore 2017, Globalheart, www.gheart.com*
6. Adrian Tase, M. G. Man, A. Tase, G. Savoiu, L. Vijan, I. Iorga-Siman. Added-on trimetazidine continuous therapy could lower the risk of incidental left ventricular dysfunction +/- heart failure in liposomal epirubicinum recipients for ovarian cancer. *Asian Pacific Congress of Cardiology, Singapore 2017, Globalheart, www.gheart.com*
7. Adrian Tase. Elita biologică a atleților de performanță și ghidurile de practică medicală cardiovasculară: discrepanțe clinice. In: Andrei Kozma, Cristiana Glavce, Constantin Balaceanu-Stolnici. *Antropologie si Educatie, Colectia Zilele Rainer, Editura Academiei Romane, Bucuresti, 2017., 474-480.*
8. Adrian G. Tase, Mihail G. Man. The pharmacological modulation of blood cholesterol at ancestral levels decreases vascular complications of atherosclerosis at populational scale. / **Modularea farmacologică a colesterolului sanguin la valori ancestrale reduce complicațiile vasculare ale aterosclerozei la scară populațională.** Simpozionul “Zilele Francisc I. Rainer – Antropologie și Demografie”, Biblioteca Academiei Române, Sala Ion Heliade Rădulescu, 27-29 Aprilie **2017**.
9. A. G. Tase, G. Savoiu, A. Tase, M. G. Man. Continuous added-on therapy with antiischaemic agents could lower the risk of incidental left ventricular dysfunction and could improve heart rate in epirubicin recipients for two thoracic cancer locations. / **Terapia aditionala continua cu agenti antiischemici poate reduce riscul disfuncției incidentale de ventricul stang si poate ameliora frecventa cardiaca la recipientii de epirubicina pentru doua localizari toracice de cancer.** Scientific Symposium “Current Trends in Natural Sciences”, University of Pitești, 20-21 aprilie **2017**.
10. A. G. Tase, M. G. Man, Anca Tase, G. Savoiu, O. Țețiu, M. Mihăilă, I. Iorga-Siman. Trimetazidine added-on therapy could lower the risk of incidental left ventricular dysfunction +/- heart failure in epirubicinum recipients

- for breast cancer, JACC (Journal of the American College of Cardiology), March 2017, Elsevier, ISSN 0735-1097, www.onlinejacc.org
11. Tase G. A., Săvoiu G., Man M. G., Iorga-Simăn I.. O abordare cronobiologică în farmacologia cardiovasculară: scheme excentrice alternative de administrare a nitraților cu acțiune prelungită la pacienți cu angina pectoris stabilă. Simpozionul “Zilele Francisc I. Rainer – Antropologie și Educație”, ediția de toamnă, Universitatea “Lucian Blaga” Sibiu, Sala Senatului, 11 Noiembrie **2016**.
12. Adrian Tase. **D RO 021346, 2016.** www.osim.ro
13. A. Tase, O. T. Țețiu, G. Săvoiu, G. Stănciulescu, M. G. Man, M. Mihăilă, I. Iorga-Simăn. Alternative eccentric schedules of long-acting nitrates administration in stable angina subjects: a chronobiological approach / **Scheme excentrice alternative de administrare a nitraților cu acțiune prelungită la pacienții cu angină stabilă: o abordare cronobiologică.** *Romanian Journal of Cardiology CNCSIS B+ EBSCO Indexed Journal, Indexed Journal in the ESC search engine, Supplement on CD, 2016.* www.romanianjournalcardiology.ro
14. A. Tase, O. T. Țețiu, G. Săvoiu, G. Stănciulescu, M. G. Man, M. Mihăilă, I. Iorga-Simăn. Continuous If channel inhibition may provide lasting decrease of persistent sinus tachycardia without airways dysfunction in lung cancer patients – our experience / **Inhibiția continuă a canalului If poate scădea durabil tahicardia sinusală persistentă cu prezervarea funcției căilor aeriene la pacienții cu cancer pulmonar - experiența noastră.** *Romanian Journal of Cardiology CNCSIS B+ EBSCO Indexed Journal, Indexed Journal in the ESC search engine, Supplement on CD, 2016.* www.romanianjournalcardiology.ro
15. A. Tase, R. Tănăsescu. Pacientul cu tromboză venoasă profundă / The patient with deep vein thrombosis. In: Masa rotundă / Round table Ce trebuie să se scrie în epicriză? / What should be written in discharge summary? *The 55th National Congress of Cardiology, 21-25 sep. 2016, Sinaia, România, 2016.*
16. A. Tase. Provocări ale fibrilației atriale în cancer / Atrial fibrillation challenges in cancer. Conferința din cadrul sesiunii: Comunicări orale 7 / Oral abstract presentations 7, Aritmii 2 / Arrhythmias 2 *The 55th National Congress of Cardiology, 21-25 sep. 2016, Sinaia, România, 2016.*

17. A.G. Tase, G. Săvoiu, O. T. Țețiu, A. Tase, M. G. Man, G. Stănciulescu, M. Mihăilă, I. Iorga-Simăn. Uninterrupted ivabradine treatment may provide lasting reduction of persistent sinus tachycardia with preserved airways physiology in lung cancer patients: a 48 months study. Best posters, p. 47, Final Programme, EBAC, ESC Congress Roma 2016, 27-31 August P482 www.escardio.org/ESC2016, <http://congress365.escardio.org/>
18. Adrian Tase. D RO 021197, 2016. www.osim.ro
19. Adrian Tase. Highlighting lifestyle measures in athletes who underwent severe cardiac diseases improves quality of life quickly and sustainable. Scientific Symposium “Current Trends in Natural Sciences”, University of Pitești, 23-24 aprilie 2016.
20. Adrian Tase. Elita biologică a atleților de performanță și ghidurile de practică medicală cardiovasculară: discrepanțe clinice. Simpozionul “Zilele Francisc I. Rainer – Antropologie și Spiritualitate”, Biblioteca Academiei Române, Sala Ion Heliade Rădulescu, 21-23 Aprilie 2016.
21. Adrian Tase. The role of renin-angiotensin-aldosterone system blockers in decreasing the risk of heart failure induced by chemotherapy in breast cancer / Rolul blocanților sistemului renină-angiotensină-aldosteron în reducerea riscului de insuficiență cardiacă indusă de chimioterapie în cancerul mamar. In: Andrei Kozma, Cristiana Glavce. Anthropology and society / Antropologie și societate, Rainer Days Collection / Colecția Zilele Rainer, Astra Museum, pgs. 417-425, 2016.
22. A. Tase. Actual insights of beta-1, 2 and 3 receptors modulation in heart failure. *Medicina Internă*, B+, vol. XIII, 2016, p. 40-41. www.srmi.ro
23. Adrian Tase. Formular tipizat, patent, 2015. www.osim.ro
24. A. G. Tase, O. Țețiu, G. Săvoiu, A. Tase, M. Mihăilă, G. Stănciulescu, C. Ușurelu, I. Iorga-Simăn. Continuous ergo-metabolic treatment added-on conventional therapy could lower the risk for incidental left ventricular dysfunction +/- heart failure in epirubicinum recipients for two cancer locations / **Tratamentul ergo-metabolic continuu adăugat terapiei convenționale poate scădea riscul disfuncției incidentale de ventricul stâng +/- insuficiență cardiacă la recipienți de epirubicină pentru două localizări tumorale maligne.** *Romanian Journal of Cardiology* CNCSIS B+ EBSCO Indexed Journal, Indexed Journal in the ESC search

engine, Supplement, pg. 112-113, **2015**.

www.romanianjournalcardiology.ro

25. **A. Tase**. Anthropological aspects of fluído-coagulant balance. **Aspecte antropologice ale echilibrului fluidocoagulant**, *The 54th National Congress of Cardiology, 17-19 sep. 2015, Sinaia, România, 2015*.
26. **Adrian Tase**. The role of beta-receptor blockers in decreasing the risk of heart failure induced by chemotherapy in breast cancer / **Rolul betablocantelor în reducerea riscului de insuficiență cardiacă indusă de chimioterapie în cancerul de sân**, *Current Trends in Natural Sciences*, included in SCIPIO, Vol. 4, Issue 7, **2015**.
<http://www.upit.ro/facultati/facultatea-de-stiinte-fst/cercetare-fst/reviste-fst/current-trends-in-natural-sciences/all-issues/2015-volume-4-issue-7.html> or <http://nasci.upit.ro>
27. **Adrian Tase**, Sorina Honțaru, Cristina Stocheci. A Model Of Optimizing Activity In Emergency Hospitals' MATUCC Type Divisions / **Un model de optimizare a activității în secții de tip USTACC din spitale de urgență**. *Management In Health / Management în sănătate*, XIX/1/2015; pp. 11-15, **2015**. journal.managementinhealth.com
28. **A. Tase**. Coronarospastic angina: where and how to treat? / **Angina coronarospastică: unde și cum o tratăm?**, *Medicina Internă*, B+, vol. XII, **2015**, p. 38-39. www.srmi.ro
29. **Adrian Tase**. The role of beta receptor blockers in decreasing the risk of heart failure induced by chemotherapy in breast cancer / **Rolul blocaților sistemului renină-angiotensină-aldosteron în reducerea riscului de insuficiență cardiacă indusă de chimioterapie în cancerul de sân**, simpozionul științific "Tendințe actuale în științele naturii", Universitatea din Pitești, 23-24 aprilie **2015**.
30. **Adrian Tase**. The role of renin-angiotensin-aldosterone system blockers in decreasing the risk of heart failure induced by chemotherapy in breast cancer / **Rolul blocaților sistemului renină-angiotensină-aldosteron în reducerea riscului de insuficiență cardiacă indusă de chimioterapie în cancerul mamar**, simpozionul "Zilele Francisc I. Rainer – Antropologie și Sănătate", Biblioteca Academiei Române, Sala Ion Heliade Rădulescu, 23-24 Aprilie **2015**.

31. Adrian Tase. The fluido-coagulant balance: an anthropological perspective / **Echilibrul fluidocoagulant: un punct de vedere antropologic**. In: Andrei Kozma, Cristiana Glavce. Anthropology and society / **Antropologie și societate**, *Rainer Days Collection / Colecția Zilele Rainer, Astra Museum*, pgs. 417-425, **2015**.
32. Călin Pop, Lucian Petrescu, Rodica Dan, Simina Crișan, Dan Filip, Antoniu Petriș, Adrian Tase, Diana Țiņț. Acute pulmonary thromboembolism / **Tromboembolismul pulmonar – embolia pulmonară**. Chapter 9 in: Călin Pop, Antoniu Petriș, Diana Țiņț, Lucian Petrescu, Gabriel Tatu-Chițoiu. Practical guide of cardiovascular emergencies / **Ghid practic de urgențe cardiovasculare**, published under the authority of the Working Group Emergency Cardiology of the Romanian Society of Cardiology / **realizat sub egida Grupului de Lucru de Cardiologie de Urgență al Societății Române de Cardiologie**, pgs. 120-145, **2014**.
33. A. Tase, O. Țețiu, G. Săvoiu, M. Mihăilă, I. Iorga-Simăn, G. Stănciulescu, L. Popescu, C. Ușurelu, M. Man. Decrease of atrial fibrillation recurrences adding mineralocorticoid receptor blockade to standard antiarrhythmic pharma therapy – a retrospective analysis. *Romanian Journal of Cardiology CNCSIS B+ EBSCO Indexed Journal, Indexed Journal in the ESC search engine, Supplement*, pg. 101-102, **2014**.
www.romanianjournalcardiology.ro
34. A. Tase, O. Țețiu, G. Săvoiu, M. Mihăilă, L. Popescu, C. Ușurelu, I. Iorga-Simăn, M. Man. HMG-CoA-reductase inhibitors added-on standard therapy may lower the risk for incident left ventricular dysfunction +/- heart failure in epirubicin recipients with gastric cancer. *Romanian Journal of Cardiology CNCSIS B+ EBSCO Indexed Journal, Indexed Journal in the ESC search engine, Supplement*, pg. 36-37, **2014**.
www.romanianjournalcardiology.ro
35. A. Tase. Cardiovascular applications of apoptosis. *The 53rd National Congress of Cardiology, 2-4 oct. 2014, Sinaia, România*, **2014**.
www.congrescardiologie.ro
36. A. Tase. Smoking – cardiology school. *The 53rd National Congress of Cardiology, 2-4 oct. 2014, Sinaia, România*, **2014**.
www.congrescardiologie.ro

37. A.G. Tase, O. Țețiu, G. Săvoiu, M. Mihăilă, I. Iorga-Simăn, G. Stănciulescu, M. Man. Mineralocorticoid receptor blocker added-on standard antiarrhythmic pharma therapy decreases the atrial fibrillation recurrences in a 24 months study. Moderated poster, p. 142, Final Programme, EBAC, ESC Congress Barcelona 2014, 30 August – 3 September P2057 www.escardio.org/ESC2014, <http://congress365.escardio.org/>
38. M. Diaconu, C. C. Georgescu, C. Pleșa, A. Tase, M. Țânțu. The variation of cardiovascular parameters in patients under propofol sedation. *Current Health Sciences Journal*, Suppl. 7, pgs. 28-30, **2014**.
39. Adrian Tase, Mihai Popescu, Monica Țânțu. Spironolactona adăugată terapiei farmacologice antiaritmice standard reduce recurențele de fibrilație atrială, *Acta Medica Transilvanica*, vol. II, nr. 3, pgs. 37-39, nr. 3, **2014**. www.amsibiu.ro
40. Adrian Tase. Contributions to the anthropology of fluido-coagulant balance, *Current Trends in Natural Sciences*, included in SCIPIO, Vol. 3, Issue 5, **2014**. <http://nasci.upit.ro>
41. C. Georgescu, M. Diaconu, C. Pleșa, M. Țânțu, A. Tase. Cardiovascular parameters variations in midazolam recipients / **Variațiile parametrilor cardiovasculari la pacienții care au primit sedare cu midazolam**, *Journal of Aeronautic Medicine and Psychology / Revista de Medicină și Psihologie Aeronautică*, Nr. 1, **2014**, BDI (ex CNCSIS B+), ISSN 1454-6205.
42. C. Georgescu, M. Diaconu, C. Pleșa, M. Țânțu, A. Tase. The Administration of midazolam as modality of anxiolysis and amnezia / **Administrarea midazolamului ca modalitate de anxioliză și amnezie**, *Journal of Aeronautic Medicine and Psychology / Revista de Medicină și Psihologie Aeronautică*, Nr. 1, **2014**, BDI (ex CNCSIS B+), ISSN 1454-6205.
43. A. G. Tase, A. Tase, O. Tetiu, G. Savoiu, M. Mihaila, M. Man, I. Iorga-Siman. Atorvastatin add-on therapy lowers the risk of incident heart failure in epirubicinum recipients for breast cancer, *World Congress of Cardiology, Melbourne 2014, Globalheart*, www.gheart.com
44. Adrian Tase, Claudiu Neacsu, Valentina Georgescu, Iuliana Ciocanea, Anca Seica, Paul Gusbeth-Tatomir. Intradialytic hypertension in end-stage renal disease patients treated by maintenance hemodialysis – a

- dynamic analysis, *World Congress of Cardiology, Melbourne 2014, Globalheart*, www.gheart.com
45. Adrian Tase, Ovidiu Țețiu, et al. Spironolactone Added-On Standard Antiarrhythmic Pharmacological Therapy Decreases The Atrial Fibrillation Recurrences in a 24 Months Study, *61st Israel Cardiac Society Congress*.
46. Adrian Tase, Monica Țânțu, Mihai Popescu, Cristina Pleșa, Magdalena Diaconu, Cristian Georgescu. The Influence of Troponin I in Improving The Accuracy in The Diagnosis of Myocardial Infarction Complications in a Geographically Defined STEMI Population / **Influența troponinei I în ameliorarea acurateții diagnostice în complicațiile infarctului miocardic într-o populație STEMI definită geografic**, *Acta Medica Transilvanica*, XIX, nr. 1, March **2014**, p. 60-61, 176-177. www.amsibiu.ro
47. Adrian Tase, Ovidiu T. Titus, Anca Tase, Gheorghe Săvoiu, Ion Iorga-Simăn, Marius Mihăilă. Add-On Therapy with HMG-CoA-Reductase Inhibitors May Lower the Risk for Incident Left Ventricular Dysfunction +/- Heart Failure in Epirubicin Recipients with Gastric Cancer, *JACC (Journal of the American College of Cardiology)*, April 1, **2014**, Volume 62, No. 12 (Supplement A), Elsevier, ISSN 0735-1097, 1260-169, p. A229. www.onlinejacc.org
48. Adrian Tase. The sequential activation of nephron – a key of therapeutic success in heart failure, *Medicina Internă*, B+, vol. XI, **2014**, p. 19-20. www.srmi.ro
49. Adrian Tase. The synergistic control of cholesterol fractions – innovative concepts in our patients, *Current Trends in Natural Sciences Scientific Papers*, volume 2 issue 4, December **2013**, ISSN (CD-ROM) 2284-9521, ISSN-L 284-9521, pgs. 79-82. www.natsci.upit.ro
50. Michel Komajda, Michael Böhm, Jeffrey Borer, Ian Ford, Henry Krum, Adrian Tase, Luigi Tavazzi, Karl Swedberg. Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure, *European Journal of Heart Failure*, Vol 15, number 1, January **2013**, ISSN 1388-9842 pgs. 79-84. www.eurjhf.oxfordjournals.org
51. Adrian Tase, Anca Tase, O. Țețiu, G. Săvoiu, G. Stănculescu, M. Mihăilă. HMG-CoA-reductase-inhibitor co-therapy lowers the risk of incident

- heart failure in farmorubicin recipients for two cancer locations.
European Heart Journal Suppl., nr. 141, p.26, **2013**. www.escardio.org
52. Kim Fox, Ian Ford, Philippe Gabriel Steg, Jean-Claude Tardif, Michal Tendera, Roberto Ferrari. A. Tase is mentioned as SIGNIFY Investigator. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronary artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. *American Heart Journal*, Volume 166, Number 4, p. 654-661, **2013**.
<http://dx.doi.org/10.1016/j.ahj.2013.06.024>
53. Daniel Gherasim, Mircea Iurciuc, Cristina Voiculet, Alina Giuca, Virgil Petrescu, Florin Maghiar, Alexandra Gherghina, Adrian Tase, Carmen Ginghina. Investigation of patient's adherence to Angiotensin II Receptor Blockers drug treatment for hypertensive patients in primary medical care (I ADHERE). *Romanian Journal of Cardiology*, CNCSIS B⁺ EBSCO ISSN:1583-2996, Vol. 23, no. 4, **2013**, p. 323-331.
www.romanianjournalcardiology.ro
54. Adrian Tase, Monica Țânțu, Mihai Popescu. A clinical assessment of the quadruple combo including eplerenone, ivabradine, clopidogrel, rosuvastatin in 144 human subjects with overt heart failure / **O evaluare clinică a combinației cvadruple cu eplerenonă, ivabradină, clopidogrel, rosuvastatină la 144 subiecți umani cu insuficiență cardiacă patentă**, *Acta Medica Transilvanica B⁺*, v. XVIII, no. 4, **2013**, p. 82-85 & 242-244.
www.amtsibiu.ro
55. Adrian Tase. Obstructive sleep apnea: a disturbing factor of multiple circadian variabilities, with major impact in cardiovascular physiology, *Time Who Governs Our Functions And Pathology*, p. 17-18, Bucharest, **2013**. www.srcronobiologie.ro
56. A. Tase, O. Țețiu, G. Săvoiu, G. Stănciulescu, M. Mihăilă, S. Marinescu. Statin co-medication lowers the risk for incident heart failure in farmorubicin recipients with breast or gastric cancer. *Romanian Journal of Cardiology*, CNCSIS B⁺ EBSCO ISSN:1583-2996, Vol. 23, Suppl. B, **2013**, p. B15-B16. www.romanianjournalcardiology.ro

57. Adrian Tase, Chronobiological features of arterial hypertension pharmacotherapy, *the 52nd National Congress of Cardiology*, program p. 058, **2013**. www.cardioportal.ro
58. Adrian Tase, Grațiela Popa, Gheorghe Săvoiu, Ovidiu Țețiu. NT-pro-BNP use in screening and prognosis of heart failure – a retrospective study. *National Congress Volume*, **2013**. www.srml.ro
59. Adrian Tase. The synergistic control of cholesterol fractions – innovative concepts. *Medicina Internă*, B+, vol. X, **2013**, p. 13-14. www.srmi.ro
60. Adrian Tase. Cardiovascular Drugs in Emergencies. In: Călin Pop, Gabriel Tatu-Chițoiu. *Cardiac Emergencies*, in press, **2013**. www.cardioportal.ro
61. Adrian Tase, Mihaela Brojboiu. Pharmaceutical formulation for cardiovascular disease prevention, patent, **2013**. www.osim.ro
62. A. G. Tase, L. Marmandiu, G. Săvoiu, O. Simionoiu, O. Țețiu, M. Mihăilă, R. Marmandiu. Varenicline therapy improves abstinence rates over 50% in smokers with cardiovascular disease – an assessment on 3044 patients. *European Heart Journal Suppl.*, **2012**. www.escardio.org
63. M. Komajda, M. Böhm, J. Borer, I. Ford, L. Tavazzi, A. Tase, K. Swedberg. Influence of background treatment with aldosterone antagonists on ivabradine effects in patients with chronic heart failure, *European Journal of Heart Failure*, published online 14 August **2012**, ISSN 1879-0844 www.eurjhf.oxfordjournals.org
64. V. Popov, A. G. Tase, S. Marinescu, M. Stancu, D. Blajan, C. Stocheci, V. Petri, M. Popescu. Medium platelet volume – an important predictive factor for aggressive evolution in acute myocardial infarction. The 17th Congress of the European Hematology Association, Amsterdam, **2012**. www.ehaweb.org
65. A. G. Tase, L. Marmandiu, R. Marmandiu, G. Săvoiu, O. Țețiu, G. Stănciulescu, M. Mihăilă, I. Iorga-Simăn. Improving the quitting rate with pharmacological therapy in cardiovascular and non-cardiovascular diseases smokers, *Circulation Suppl.*, World Congress of Cardiology, Dubai, **2012**. www.circ.ahajournals.org & www.wccondemand.org
66. M. Komajda, M. Böhm, J. S. Borer, I. Ford, L. Tavazzi, A. Tase, K. Swedberg. Ivabradine improves clinical outcomes in patients with chronic systolic heart failure taking aldosterone antagonists: findings from SHIFT trial. *Heart Failure* **2012**, Belgrade. www.escardio.org/HFA

67. A.G. Tase, V. Popov, A.M. Vlădăreanu, M.C. Stancu, G. Săvoiu, M. Mihăilă, G. Stănciulescu, O. Țețiu. An updated risk factors assessment for stroke and myocardial infarction in patients with chronic myeloproliferative neoplasms. *Rom. Heart J., B+* ISSN 1583-2996, **2012**. www.cardioportal.ro
68. A. Tase, T. Nanea. Highlights of RSC chapters. *Rom. Heart J., B+* ISSN 1583-2996, **2012**. www.cardioportal.ro
69. A. Tase, S. Marinescu, M. Mihăilă, I. Iorga-Simăn, O. Țețiu. The pressure preservation with digoxin in patients with chronic heart failure in sinus rhythm – a 7 years retrospective study. *Medicina internă, B+*, vol. VIII, **2012**. www.srmi.ro
70. A. Tase. Are betablockers still preferred in cardiovascular disease? – a state-of-the-art. *Medicina internă, B+*, vol. VIII, **2012**. www.srmi.ro
71. A. G. Tase, E. Dinu, M. Mihăilă, O. Țețiu. Troponin I improves the diagnostic and prognosis accuracy in acute myocardial infarction with ST elevation – a study on 576 patients. National Congress Volume, **2012**. www.srml.ro
72. Adrian Tase. Advices for your Heart, DVD, 45 minutes, *Bitpress*, **2012**. www.bitpress.ro
73. Adrian Tase, Mihaela Brojboiu. Polipilula cardiologică RICE, patent published as abstract in 29/07/**2011**. www.osim.ro
74. A.G. Tase, V. Popov, A.M. Vlădăreanu, M.C. Stancu, G. Săvoiu, M. Mihăilă, G. Stănciulescu, O. Țețiu. A risk factors assessment for stroke and myocardial infarction in patients with chronic myeloproliferative neoplasms. *European Heart Journal Suppl.*, **2011**. www.escardio.org
75. V. Popov, A.M. Vlădăreanu, M. Stancu, A.G. Tase. The risk of stroke and myocardial infarction in patients with myeloproliferative neoplasms - a study of the importance of platelet aggregation, *ISTH Congress, Kyoto*, **2011**. www.isth.org
76. Țiņț D., Rădoi M, Petriș A., Datcu D. M., Sinescu C., Craiu E., Vinereanu D., Dorobanțu M., Ionescu D. D., Macarie C., Ginghină C., Georgescu C., Șerban L., Stănciulescu P., Petrescu I., Petrescu L., Tase A., Nechita E., Topolnițchi L, Benedek I., Dobreanu D. ,Gârbea S., Gheorghe A. D., Vida-Simiti L., Olinic D., Pop C., Tatu-Chițoiu G., on behalf of RO-STEMI investigators. [Rom] The age, cardiovascular risk factors, therapy and in-

- hospital mortality in patients with STEMI. A STEMI Romanian Registry (RO-STEMI) report. *Romanian Journal of Cardiology* Vol. 26, No. 1, 2011:4-13. ISSN 1583-2996.
77. Adrian Tase. Are there specific biomarkers in diastolic heart failure? 19th BCLF Book, *Balkan Clinical Laboratory Federation*, Bucharest, **2011**. www.bclf-2011.org
78. A. Tase, R. Marmandiu, S. Marinescu, O. Țețiu, I. Iorga-Simăn, D. Blăjan. Assessment of antismoking therapy – a study on 1973 patients. *Rom. Heart J., B+* ISSN 1583-2996, **2011**. www.cardioportal.ro
79. A. Tase, G. Săvoiu, M. Mihăilă, I. Iorga-Simăn, G. Stănciulescu, M. Stancu, O. Țețiu. Systolic blood pressure & pulse pressure preservation in sinus rhythm chronic heart failure patients – 5 years experience. *Rom. Heart J., B+* ISSN 1583-2996, **2011**. www.cardioportal.ro
80. Adrian Tase. Essential Pharmacology, from bench to bedside, *University of Pitești Publishing House*, **2011**, ISBN: 978-606-560-205-2, book, 232 pages. www.upit.ro
81. A. Tase. The brown adipose tissue – a spot of colour on the cardiovascular risk factors map. *Medicina internă, B+*, vol. VIII, **2011**. www.srmi.ro
82. Adrian Tase, Ovidiu Țețiu, Marius Mihăilă, Gabriela Stănciulescu, Cristina Trache, Daniel Blăjan. A 24 months study with eplerenone add-on antiarrhythmic pharmacotherapy reducing the occurrence of atrial fibrillation episodes, *Circulation Suppl.*, World Congress of Cardiology, Beijing, **2010**. www.circ.ahajournals.org & www.wcondemand.org
83. The SHIFT Study Group (including Adrian Tase as PI). SHIFT Study, *The Lancet*, **2010**.
84. Adrian Tase, Ovidiu Țețiu, Marius Mihăilă, Gabriela Stănciulescu, Cristina Trache, Daniel Blăjan. Eplerenone on the top of antiarrhythmic treatment decreases the recurrence of atrial fibrillation episodes. *Therapeutics, Pharmacology, and Clinical Toxicology*, Vol. XV, suppl. 2, **2010**. www.farmacologie.ro
85. The Euro Heart Survey Study Group (including Adrian Tase as PI) Euro Heart Survey Snapshot, *European Heart Journal*, **2010**. www.escardio.org
86. G. Tatu-Chițoiu, D. Vinereanu, D. Deleanu, ..., A. Tase. The first Romanian registry RO-STEMI, **2010**. www.cardioportal.ro

87. Tase A. G., Marinescu S., Țețiu O., Iorga-Simăn I., Săvoiu G., Blăjan D., Mihăilă M.. The influence of heart rate lowering antihypertensive combos upon heart rate variability. *Rom. Heart J.*, ISSN 1583-2996, **2010**. www.cardioportal.ro
88. Tase A. G., Săvoiu G., Mihăilă M., Iorga-Simăn I., Stănciulescu G., Trache C., Țețiu O.. The decrease of atrial fibrillation recurrences by specific mineralocorticoid receptor blockade. *Rom. Heart J.*, ISSN 1583-2996, **2010**. www.cardioportal.ro
89. Adrian Tase. Essential Management in the Clinical Arena, *University of Pitești Publishing House*, **2010**, ISBN 978-606-560-154-3, book, 300 pages. www.upit.ro
90. Adrian Tase. The highway of life, Audio CD, 45 minutes, **2010**, ISBN 978-606-560-173-4.
91. Tase A. G., Mihăilă M., Stănciulescu G., Trache C., Blăjan D., Țețiu O.. Eplerenone add-on antiarrhythmic pharmacotherapy reduces the occurrence of atrial fibrillation episodes in a 18 months study. *Final program and abstract book, pag.50. 6th Global CardioVascular Clinical Trialists Forum, Paris, Pullman Tour Eiffel, France, 2009*. www.globalcvctforum.com/
92. G. Tatu-Chițoiu, C. Arsenescu-Georgescu, K. Babeș, I. Benedek, R. Căpârneanu, M. Cintează, E. Craiu, D. M. Datcu, D. Deleanu, D. Dobreanu, M. Dorobanțu, Ș. I. Drăgulescu, V. Firăstrău, C. Ginghină, D. D. Ionescu, C. Macarie, I. Manițiu, B. Minescu, Ș. Moț, E. Nechita, C. Olariu, D. Olinic, F. Orțan, I. Petrescu, L. Petrescu, A. Petriș, C. Pop, M. Rădoi, C. Sinescu, P. Stănciulescu, L. Șerban, Adrian Tase, M. Tomescu, L. Vida-Simiti, D. Vinereanu, M. Vintilă, M. Vlădoianu, M. Andrițoiu, I. Ș. Balea, A. Bălăceanu, L. Chiriac, C. David, D. Dimulescu, B. Ghencea, G. A. Dan, S. Gîrbea, L. Kiss, G. Ludușan, I. Mălăescu, T. Nanea, V. Stancu, L. Topolnițchi (din partea investigatorilor RO-STEMI). RO-STEMI Societatea Română de Cardiologie. Primul registru român pentru infarctul miocardic acut cu supradenivelare de segment ST (1997-2009) raport final, *Editura Medicală Amaltea*, www.amaltea.ro
93. Tase A. G., Marinescu S. M.. Has the S-T Segment Elevation in aVR any value in AMI? *Rom. Heart J.*, ISSN 1583-2996, **2009**. www.cardioportal.ro

94. Tase A. G., Mihăilă M., Stănciulescu G. E., Blăjan D., Țețiu O. T..
Spironolactone added-on antiarrhythmic drugs reduces the occurrence
of atrial fibrillation episodes. *Rom. Heart J.*, ISSN 1583-2996, vol. XXIV,
suppl. A, **2009**. www.cardioportal.ro
95. Tase A. G.. Cardiovascular Medicine: from tradition to innovation – 17
APCC 09, *InfoCard, a Supplement of Rom. Heart J.*, ISSN 1583-2996, **2009**,
pag. 20. www.cardioportal.ro
96. A. G. Tase. The expanded mandate of RAAS modulators. *Medicina
Internă CNCSIS*, vol. VI, nr. 2, **2009**, p. 18-19. www.srmi.ro
97. A. G. Tase, S. Marinescu, O. T. Țețiu, M. Mihăilă, D. Blăjan. A specific
antihypertensive treatment in cancer patients with hypertension
subsequent to molecular targeted therapy. *Medicina Internă CNCSIS*, vol.
VI, nr. 2, **2009**, p. 115. www.srmi.ro
98. Vîjan E. L., Tase A. G.. DNA modification and cancer - spectral study of
bleomycin-DNA interaction. *Revista de Chimie*, **2008**.
www.revistadechimie.ro
99. The BEAUTIFUL Study Group (including Tase A.G. as Principal
Investigator). The BEAUTIFUL Study: Randomized Trial of Ivabradine in
Patients with Stable Coronary Artery Disease and Left Ventricular Systolic
Dysfunction - Baseline Characteristics of the Study Population.
*Cardiology - International Journal of Cardiovascular Medicine, Surgery,
Pathology and Pharmacology, Karger*, **2008**.
100. Tase A. G., Nicolae C. Balanced Score Card – management tool in hospitals reform. *Management in
Health*, **2008**. www.managementinsanatate.ro
101. Tase A. G., Hontaru S.. The Romanian Health Reform Law – a critical appraisal in corelation with other
reglementations. *Management in Health*, **2008**. www.managementinsanatate.ro
102. Tase A. G.. Key decisions in cardiovascular pharmacology, *Pharmakon*, **2008**; ISSN 1584-0514.
103. Tase A. G.. The left ventricular post-infarction remodelling – an update, *Pharmakon*, **2008**; ISSN 1584-
0514.
104. Tase A. G., Tase A.. Optimizing the pharmacological treatment of pain (I). *Pharmakon* VII (84):12-14,
2008; ISSN 1584-0514.
105. Tase A. G., Tase A.. Optimizing the pharmacological treatment of pain (II). *Pharmakon* VII (85):12-13,
2008; ISSN 1584-0514.
106. Tase A. G., Man M.. Angiogenic therapy – a new treatment paradigm for coronary artery disease (I).
Pharmakon VII (80):16-17, **2008**; ISSN 1584-0514.
107. Tase A. G., Man M.. Angiogenic therapy – a new treatment paradigm for coronary artery disease (II).
Pharmakon VII (81):12-13, **2008**; ISSN 1584-0514.
108. Tase A. G.. The arterio-venous thrombosis – a continuum of the same disease? (I). *Pharmakon* VII
(82):14-15, **2008**; ISSN 1584-0514.
109. Tase A. G.. The arterio-venous thrombosis – a continuum of the same disease? (II). *Pharmakon* VII
(83):14-15, **2008**; ISSN 1584-0514.

110. Tase A. G.. News from ACC 2008. *InfoCard, XIII, 43:9, a Supplement of Rom. Heart J.*, ISSN 1583-2996, **2008**. www.cardioportal.ro
111. Adrian Tase, Luminița Tițu. General Objectives and Methods in HIV/AIDS Surveillance. Book chapter in: Donev D., Pavlekovic G., Kragelj L.Z.. Health Promotion and Disease Prevention. A handbook for teachers, researchers, health professionals and decision makers. FPP-SEE Forum for Public Health Collaboration in South-Eastern Europe, *Hans Jacobs Publishing Company Germany*, ISBN 978-3-89918-169-2, **2007**.
112. Ferrari R. and the PREAMI Investigators (including Tase A. G. as Principal Investigator). The PREAMI Study: The Perindopril Remodelling in Elderly with Acute Myocardial Infarction, *Arch. Intern. Med*, **2006**.

Other 147 papers published in other medical journals.

222 conferences with medical and/or university audiences.

120 press conferences with medical topics.